Completed Projects

Rheumatoid arthritis (RA) is an autoimmune inflammatory disorder, primarily characterized by synovial joint inflammation, affecting ~0.5 to 1% of the overall population (~2900000 patients in the EU) and is more common in women than men (3:1). RA is a huge public health problem as it leads over time to permanent disability. There is no cure for RA but remission of symptoms is more likely when treatment begins early. However, approximately 40% of RA patients fail to achieve even 20% improvement in disease activity, with significant disability remaining in about a third of patients, and major work-related and social costs for patients and society. In addition, 10-20% of patients do not respond to any current medication, pointing to considerable disease heterogeneity and the need for testing and developing new drugs. A further point related to RA heterogeneity, is that there are no biomarkers of treatment response to individual drugs. Thus, a number of unmet needs still persist particularly related to response/non-response to powerful but expensive drugs. The main goal of FLAMIN-GO is thus to create an advanced, personalized joint-on-chip platform designed to faithfully replicate the complex characteristics of RA-affected joints, enabling personalised clinical trials-on-chip, for personalising treatment by identifying the most effective drug for each individual patient, as well as accelerating the discovery and testing of novel therapeutic targets, paving the way for the development of new drugs.

Liver cirrhosis is late-stage liver fibrosis (scarring) caused by liver diseases or conditions such as hepatitis B or C virus infection, obesity, type-2 diabetes mellitus or chronic alcoholism. There is no treatment to reverse advanced liver cirrhosis; it is always preceded by slowly developing, asymptomatic, liver fibrosis. Early diagnosis of liver fibrosis is crucial for the estimated 10 million Europeans with the undetected disease. The EU-funded LiverScreen project aims to develop a novel screening approach to identify asymptomatic liver fibrosis and cirrhosis among the general population. Researchers will identify groups at high risk of chronic liver disease and screen their liver stiffness with the innovative transient elastography technology. The 8 collaborating European countries will use 34 000 subjects to develop the screening and demonstrate its accuracy, clinical value, cost-effectiveness, acceptability and implementation potential

Horizon 2020 GIFT project (01/01/2019-30/06/2023). EU CORE has been appointed as external expert to support the project coordinator in the financial reporting and for legal issues stemming

Horizon 2020 ITN Renal ToolBox project (01/11/2018-31/10/2022) EU CORE has been appointed as external expert to support the project coordinator in the financial reporting and for legal

Horizon 2020 ITN PREMUROSA project (01/01/2020 to 30/09/2024).

INTERREG Italy-Switzerland GETRI (Gestione Transfrontaliera Trasporto Inerti Intermodale) project (20/11/2018 to 20/11/2021). EU CORE has been selected as external expert of the Lead Partner, Provincia di